Genprex, Inc. (GNPX) fundamentals score
Genprex is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Its oncology platform utilizes its systemic, non-viral ONCOPREX Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.0 out of 10, Weak long-term fundamentals
- Growth: 3.5/10
- Profitability: 1.0/10
- Financial health: 5.8/10
- Earnings quality: 10.0/10
- Valuation: 1.5/10
Scores are calculated from Genprex, Inc.’s SEC filings, using the 12 months through 2022-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10